MEA Ablation Technologies Market

MEA Ablation Technologies Market Size (2022 to 2027)

The Ablation Technologies Market size in the Middle East & Africa has been valued at USD 297.44 Million in 2022 and is projected to reach USD 510.30 Million by 2027, at a CAGR of 11.40% between 2022 to 2027.

The rising number of cancer and cardiac arrests, the growing geriatric population, and shifting to the preference for minimal non-invasive procedures are likely to accelerate the growth of the MEA ablation technology market during the forecast period. According to statistics from the World Health Organization, nearly 17.56 million deaths each year are associated with cardiovascular disease, of which atrial defibrillation is a significant disorder. In addition, the incidence of atrial fibrillation increases with age, affecting almost one in 20 people aged 65 and over.

Ablation has various advantages over traditional treatment procedures like more minor surgical complications, less risk of infection, shorter hospital stays, reduced post-operative care, less pain, faster recovery, smaller incisions, and better aesthetic and low-risk infections. In addition, ablation has successfully removed cancerous growths and lymph nodes for diagnostic biopsies and staging studies. This helps surgeons to develop accurate and appropriate cancer treatment plans. According to WHO statistics, in 2019, more than 19 million people worldwide would have developed new types of cancer, around 39 million people are believed to be suffering from cancer, and more than 10 million deaths due to cancer-induced complications. Thus, the constant increase in the number of patients with cancer and cardiovascular diseases will lead to significant demand for ablation procedures in the years to come. All these factors will generate several opportunities which lead to the growth of the MEA ablation technologies market during the forecast period.

However, the high cost of the ablation process and the rigid regulatory approval process are likely to slow the growth of the ablation technology market during the forecast period mentioned above. In addition, specific therapeutic challenges related to the effectiveness of ablation techniques such as scarring, pigmentation, and others are key challenges faced by the market.

The availability of effective conventional therapies as a significant/ first-line of treatment option is an essential constraint to the market's growth. Conventional therapies such as surgery, chemotherapy, and radiation therapy are preferred as cancer treatment due to the widespread awareness of these traditional modalities, low uptake of advanced treatment options, and the reluctance of oncologists to switch to conventional treatments, especially in developing economies.

This research report on the MEA ablation technologies market has been segmented and sub-segmented into the following categories.

By Product: 

• Light/Laser Ablators
• Radiofrequency (RF) Ablators
• Electrical Ablators
• Ultrasound Ablators
• Microwave Ablators
• Cryoablation Devices
• Hydrothermal Ablators

By Type: 

• Light/Laser Ablation
• Radiofrequency Ablation
• Electrical Ablation
• Ultrasound Ablation
• Cryoablation
• Microwave Ablation
• Hydrothermal Ablation

By Application: 

• Cardiovascular Disease Treatment
• Cancer Treatment
• Ophthalmologic Treatment
• Gynecologic Treatment
• Pain Management
• Urologic Treatment
• Orthopedic Treatment
• Cosmetic Surgery
• Other Treatments  

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the Middle East dominates the MEA ablation technologies market due to the rapid growth of the technologies, high rate of adoption of ablation devices, and extensive senior population. On the other hand, the regional market in the United Arab Emirates, Qatar, Oman, and Saudi Arabia is anticipated to experience a steady growth rate due to the large population base, increasing healthcare expenditure, good reimbursement policies, and high prevalence of cancer.

Emerging markets in Turkey, Kuwait, Bahrain, and Egypt will see good growth opportunities in the MEA ablation technology market, owing to factors such as initiatives undertaken by public and private sectors, continuous improvements in healthcare infrastructure, growing patient healthcare awareness, and availability of ablation devices.

Regions in Africa will also see growth due to relatively low treatment procedures and improving spending on medical care. In addition, there is also increased incidence and prevalence of lifestyle-related diseases, such as heart disease and cancer.

KEY MARKET PLAYERS:

Companies playing a leading role in the Middle East & Africa ablation technologies market profiled in the report are Biosense Webster, Inc., St. Jude Medical, Inc., Boston Scientific Corporation, AngioDynamics, Inc., AtriCure, Inc., Smith & Nephew plc, Galil Medical Inc., CONMED Corporation, Olympus Corporation, Covidien PLC, Medtronic, Inc., and BSD Medical Corporation.